Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed
Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed radiography market (SCAN 5/13/98).
Berman's appointment comes soon after other management moves by the company. COO and CFO Craig Klosterman has left the company to join Informatica, a private software company. Replacing Klosterman as CFO is vice president of finance Dean MacIntosh. Also, the company has hired Duncan Moffat for the newly created post of vice president of operations.
In other Lumisys news, the company has begun a road show to commemorate the launch of its ACR-2000 desktop computed radiography unit, which Lumisys plans to sell through the same network of OEMs that market its film digitizers. Vice president of channel development and sales Scott Evers is traveling around the U.S. in a new yellow Volkswagen Beetle to demonstrate the unit to clinics, hospitals, OEMs, VARs, and systems integrators. The trip will conclude at this year's Radiological Society of North America meeting, with commercial deliveries expected to begin in early 1999.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.